Enisamium

Summary

Enisamium (CHEMBL1740071) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 227.28 Da · C14H15N2O+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1740071
Name	Enisamium
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2132298
Molecular formula	C14H15N2O+
Molecular weight	227.28
InChIKey	QOEJDHLJOKRPJG-UHFFFAOYSA-O

SMILES: C[N+]1=CC=C(C=C1)C(=O)NCC2=CC=CC=C2

IUPAC name: N-benzyl-1-methylpyridin-1-ium-4-carboxamide

Also known as: Enisamium cation, Enisamium ion, enisamium-iodide

Parent form; salt/anhydrous children: CHEMBL1716983

Patent coverage: 6 distinct patent families (9 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).